<DOC>
	<DOCNO>NCT02493582</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Apatinib combine cytokine-induced killer cell ( CIK ) v Apatinib alone third line therapy advance lung adenocarcinoma patient wild-type EGFR</brief_summary>
	<brief_title>The Study Apatinib Plus CIK Third Line Therapy Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR</brief_title>
	<detailed_description>400 patient stage IIIB &amp; IV lung adenocarcinoma receive surgery chemotherapy , randomly divide group A（Apatinib plus CIK treatment ) group B（Apatinib ) , randomize ratio 1:1 . Patients group A receive 3 cycle CIK treatment ( every 1 year ) Apatinib ( continuous ) .Patients group B receive Apatinib ( continuous ) .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm Lung adenocarcinoma Wldtype EGFR Stage IIIB/IV Failure prior chemotherapy Life expectancy 3 month Tissue sample desire genomic study Age ≥ 18 year Performance status ( WHO ) &lt; 3 Adequate bone marrow function ( absolute neutrophil count &gt; 1000/mm^3 , platelet count &gt; 100000/mm^3 , hemoglobin &gt; 9gr/mm^3 ) Adequate liver ( bilirubin &lt; 1.5 time upper limit normal SGOT/SGPT &lt; 2 time upper limit normal ) renal function ( creatinine &lt; 2mg/dl ) Presence twodimensional measurable disease . The measurable disease irradiate Informed consent Lung squamous cell carcinoma type NonSmall cell lung cancer Small cell lung cancer Have previously receive TKIs Hemoglobin＜8.0 g/dL , White blood cell ＜3 X 10^9/L ; Platelet count ＜75 X 10^9/L ; alanine aminotransferase , glutamicoxalacetic transaminase , blood urine nitrogen creatinine normal limit 3.0 time Known suspect allergy investigational agent agent give association trial Pregnant lactating patient Known history Human Immunodeficiency Virus ( HIV ) , Hepatitis C Virus ( HCV ) TreponemaPallidun ( TP ) infection Patients suffer serious autoimmune disease Patients use long time use immunosuppressant Patients active infection Patients suffer serious organ dysfunction Patients suffer cancer Other situation researcher consider unsuitable study . Other concurrent uncontrolled illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>CIK</keyword>
	<keyword>Apatinib</keyword>
	<keyword>Lung Adenocarcinoma</keyword>
</DOC>